FY2025 EPS Forecast for Ovid Therapeutics Lowered by Analyst

Ovid Therapeutics (NASDAQ:OVID) – Equities researchers at Wedbush dropped their FY2025 earnings per share (EPS) estimates for shares of Ovid Therapeutics in a research report issued to clients and investors on Wednesday, November 12th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($0.39) per share for the year, down from their previous forecast of ($0.36). The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. Wedbush also issued estimates for Ovid Therapeutics’ Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.27) EPS.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Ovid Therapeutics had a negative net margin of 550.04% and a negative return on equity of 63.79%. The company had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.17 million.

Several other research firms have also issued reports on OVID. Oppenheimer initiated coverage on shares of Ovid Therapeutics in a research report on Thursday, October 9th. They set an “outperform” rating and a $7.00 price target on the stock. B. Riley restated a “buy” rating on shares of Ovid Therapeutics in a research note on Friday, October 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ovid Therapeutics in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered Ovid Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $3.70.

Ovid Therapeutics Price Performance

OVID stock opened at $1.31 on Monday. The company’s 50-day moving average price is $1.44 and its two-hundred day moving average price is $0.84. The firm has a market cap of $92.93 million, a P/E ratio of -2.61 and a beta of 0.31. The company has a quick ratio of 4.24, a current ratio of 4.24 and a debt-to-equity ratio of 0.28. Ovid Therapeutics has a 12 month low of $0.24 and a 12 month high of $2.01.

Institutional Investors Weigh In On Ovid Therapeutics

Hedge funds have recently modified their holdings of the company. Affinity Asset Advisors LLC bought a new stake in Ovid Therapeutics during the 1st quarter worth $208,000. XTX Topco Ltd bought a new position in Ovid Therapeutics in the first quarter valued at about $29,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Ovid Therapeutics during the second quarter valued at about $53,000. Nuveen LLC bought a new stake in shares of Ovid Therapeutics during the first quarter worth about $37,000. Finally, Adage Capital Partners GP L.L.C. increased its stake in shares of Ovid Therapeutics by 15.0% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,150,000 shares of the company’s stock valued at $359,000 after buying an additional 150,000 shares during the period. Institutional investors and hedge funds own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.